- Overview of mild traumatic brain injury
- Current diagnostic challenges
- Established assessment tools
- Emerging technologies in evaluation
- Recommendations for clinical practice
Mild traumatic brain injury (mTBI), often referred to as concussion, is a common clinical condition that results from an external force to the head or body, leading to a transient disruption in brain function. It accounts for the majority of traumatic brain injuries globally and is most frequently observed in contact sports, road traffic accidents, falls, and military environments. Individuals with mTBI often present with subtle cognitive, physical, emotional, or sleep-related symptoms that may resolve quickly or persist for weeks or even months, affecting daily functioning and quality of life.
mTBI is typically characterised by a brief loss or alteration of consciousness, post-traumatic amnesia, or disorientation at the time of injury. Crucially, these injuries rarely result in detectable abnormalities on standard neuroimaging, making diagnostic evaluation heavily reliant on clinical assessment tools and detailed history taking. The Glasgow Coma Scale, a widely used method for evaluating the severity of brain injuries, helps to assess eye, verbal and motor responses. Scores of 13 to 15 on the Glasgow Coma Scale are indicative of mTBI, although this alone may not capture the full extent of cognitive or functional impairment.
In both civilian and athletic settings, tools such as the Sport Concussion Assessment Tool (SCAT) have gained prominence for aiding in standardised evaluation. The SCAT combines symptom checklists, cognitive screening, coordination tests, and balance assessments, offering a comprehensive approach to initial sideline concussion assessment. These types of assessment tools play a vital role in helping clinicians decide on further evaluation or the appropriate timing for return-to-play or return-to-duty decisions.
Despite its classification as “mild,” the potential long-term implications of mTBI, including cumulative effects from repeated injuries, highlight the importance of early detection and management. A nuanced understanding of the condition is essential for clinicians, policy makers, and care providers, as accurate diagnosis and monitoring are foundational to effective treatment and prevention of further injury.
Current diagnostic challenges
Accurate diagnosis of mild traumatic brain injury (mTBI) presents several clinical challenges, primarily due to the subtle and often transient nature of symptoms which may not manifest immediately following the injury. One of the principal difficulties arises from the subjective reliance on self-reported symptoms such as headache, dizziness, confusion, or memory impairment. These complaints may overlap with other conditions, such as fatigue or psychological stress, complicating the clinician’s ability to confidently distinguish mTBI from other diagnoses based on symptoms alone.
Standard neuroimaging tools such as CT and MRI scans frequently do not detect abnormalities in cases of mTBI, particularly in the acute phase. While helpful in ruling out more severe structural injuries, these imaging modalities offer limited value in identifying the diffuse axonal injuries or subtle neurometabolic changes often associated with mTBI. As a result, clinicians must depend on clinical judgement bolstered by assessment tools like the SCAT or Glasgow Coma Scale, both of which have limitations in specificity and sensitivity, especially outside of athletic or emergency settings.
Another layer of complexity comes from the variability in presentation across different populations. Children, older adults, and individuals with pre-existing neurological or psychiatric conditions may exhibit atypical symptom patterns or have difficulty articulating their experiences, leading to underdiagnosis or misdiagnosis. Additionally, cultural and linguistic differences can impede standardised assessment, particularly when tools are not translated or validated across diverse demographic groups.
Timeliness of evaluation poses further challenges. In many cases, individuals do not seek immediate medical attention after sustaining a blow to the head, especially if consciousness is not lost and symptoms appear minimal. This delay can complicate the identification and documentation of acute signs, which are critical for supporting a diagnosis of mTBI. Moreover, in environments such as sports or military operations, there is often a social or occupational pressure to under-report symptoms, leading to further under-recognition of injury.
Inconsistency in clinician training and experience with mTBI contributes to diagnostic variance. While tools like the SCAT and Glasgow Coma Scale offer structured frameworks, their effective use relies on proper interpretation and contextual understanding. Without standardisation in application, results can vary significantly between practitioners or healthcare settings, impeding longitudinal monitoring and continuity of care.
Collectively, these diagnostic challenges underline the need for improved, objective biomarkers and refined assessment tools that can be reliably utilised across diverse clinical environments. Until such advancements are fully integrated into practice, early and accurate diagnosis of mTBI will continue to rely heavily on clinician expertise, patient cooperation, and vigilant use of available diagnostic frameworks.
Established assessment tools
Several standardised assessment tools have been developed to support clinicians in evaluating mild traumatic brain injury (mTBI), helping to identify symptoms, monitor progression and guide management decisions. The most widely used and historically established among these is the Glasgow Coma Scale (GCS), which assesses a patient’s level of consciousness by scoring verbal, motor, and eye-opening responses. While a GCS score of 13 to 15 suggests mTBI, it is limited in capturing subtle cognitive or functional deficits and lacks diagnostic sensitivity for more nuanced neurological impairments associated with mild injury.
In the realm of sports, the Sport Concussion Assessment Tool (SCAT), currently in its sixth iteration as SCAT6, is considered the standard for on-field and sideline assessment. The SCAT provides a multi-domain approach, incorporating symptom evaluation, cognitive and neurological screening, balance examination, and coordination tasks. It is particularly valuable in the immediate aftermath of an impact, offering a structured method of assessing acute changes that may not be evident on clinical imaging. However, its application is primarily validated for use in individuals aged 13 and above, and its accuracy may diminish with delayed administration post-injury.
For evaluating younger populations, the Child SCAT6 offers a tailored approach suitable for children aged 6 to 12, accounting for age-appropriate symptom descriptors and cognitive expectations. This adaptation is critical given the developmental variability in this age group, which can affect both symptom expression and the reliability of self-reporting.
Outside the sporting environment, other tools such as the Standardised Assessment of Concussion (SAC) and the Military Acute Concussion Evaluation (MACE) have been introduced. The SAC is a brief cognitive test evaluating orientation, immediate memory, concentration, and delayed recall, often used in combination with other tests to supplement clinical assessment. The MACE, developed for use in military settings, also includes symptom screening and cognitive testing, adjusted for use in field-based environments where rapid triage is necessary.
Balance assessment is another cornerstone of mTBI evaluation. Tools such as the Balance Error Scoring System (BESS) enable clinicians to detect postural instability, a hallmark feature of concussion. While relatively low-tech and easy to administer, BESS performance can be influenced by fatigue, pain, or musculoskeletal injury, and therefore is most informative when interpreted within a broader diagnostic framework.
Self-report symptom checklists are frequently employed to capture subjective complaints associated with mTBI. Instruments such as the Post-Concussion Symptom Scale (PCSS) allow patients to rate the severity of symptoms including headache, fatigue, irritability, and difficulty concentrating. Although useful for monitoring symptom evolution over time, these tools are inherently subjective and can be affected by mood, personality, and situational factors.
Neuropsychological testing offers more in-depth cognitive assessment and is particularly valuable in cases where symptoms persist beyond the typical recovery period of mTBI. Baseline cognitive testing, often used in athletic settings, allows for post-injury comparison to evaluate deficit. However, its utility depends on pre-injury assessments being available and consistent, which may not be feasible in general clinical practice.
Despite the usefulness of these established assessment tools, limitations persist, particularly in terms of standardisation and sensitivity. Many tools rely on self-reported data or performance that may be influenced by external variables, and few are validated across all demographic groups. Nevertheless, when used in combination—such as pairing SCAT with symptom ratings and neurocognitive screening—they provide a practical and structured foundation for the identification and follow-up of mTBI in a variety of clinical and non-clinical settings.
Emerging technologies in evaluation
Advancements in technology are revolutionising the evaluation of mild traumatic brain injury (mTBI), offering new avenues to complement traditional assessment tools such as the Glasgow Coma Scale and SCAT. These innovations aim to enhance diagnostic accuracy by providing objective measures of brain function and physiological changes, thereby addressing many of the limitations associated with subjective symptom reporting and observer-based scoring systems.
One of the most promising areas of development is the use of portable neuroimaging devices. Technologies such as near-infrared spectroscopy (NIRS) and portable electroencephalography (EEG) are gaining traction in both research and clinical environments. NIRS estimates cerebral oxygenation and haemodynamic changes, potentially detecting subtle disruptions in brain metabolism associated with mTBI. Meanwhile, compact EEG systems allow for rapid assessment of electrical activity in the brain, offering insight into functional disturbances that are not apparent on conventional imaging. These tools are especially valuable in pre-hospital or field settings, such as sports sidelines or military operations, where immediate evaluation is critical.
Another burgeoning field involves blood-based biomarkers. Research has identified several potential biomarkers, such as glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), which are released into the bloodstream in response to brain injury. The approval of biomarker-based tests for use in emergency departments marks a significant step forward in leveraging biological indicators for early diagnosis. These tests may be used in conjunction with clinical assessment tools to determine whether imaging is necessary or to support a diagnosis of mTBI in ambiguous cases.
Digital platforms are also reshaping the landscape of concussion evaluation. Mobile applications and tablet-based cognitive tests offer instant results for domains like memory, attention, reaction time, and processing speed. These digital tools are capable of longitudinal monitoring and can flag deviations from an individual’s baseline performance, which is particularly useful in sports and occupational contexts. Furthermore, gamified testing environments may improve engagement and performance reliability, particularly in adolescents and young adults where traditional testing can be less effective.
Wearable technology presents another innovative means of tracking and assessing potential mTBI events. Accelerometers and gyroscopes embedded in helmets or headbands measure impact forces in real-time and may alert medical staff when a potentially injurious event occurs. While these devices cannot diagnose mTBI alone, they provide valuable context that can trigger more comprehensive evaluation using tools like the SCAT6 or neuroimaging. Their integration into contact sports and military gear exemplifies a proactive approach to managing head trauma risk.
Virtual reality (VR) and artificial intelligence (AI) are emerging as high-tech solutions for nuanced assessment and rehabilitation. VR-based systems can simulate real-world tasks while tracking eye movement, balance, and coordination under controlled conditions. These simulations test cognitive and sensory integration in a way that mimics everyday demands more accurately than static paper-based tools. Meanwhile, AI algorithms are being developed to analyse large datasets from assessments, imaging, and wearables to predict outcomes, track recovery trajectories, and personalise treatment strategies.
Though still in various stages of validation and accessibility, these technologies hold promise for transforming the management of mTBI. They offer opportunities for earlier detection, more precise monitoring, and improved clinical decision-making. However, integration into routine practice will require rigorous standardisation, appropriate training, and careful consideration of data privacy and equity across diverse patient populations. Nevertheless, as part of an evolving toolkit alongside established instruments like the Glasgow Coma Scale and SCAT, emerging technologies signal a future where the complex nature of mTBI can be addressed more comprehensively and objectively.
Recommendations for clinical practice
To enhance the evaluation and management of mild traumatic brain injury (mTBI) in clinical settings, standardising the use of evidence-based assessment tools is imperative. Clinicians should adopt a multimodal approach that combines subjective symptom reporting with objective measures, utilising instruments such as the SCAT, Glasgow Coma Scale, and neurocognitive screening tests according to patient age and context. While the Glasgow Coma Scale remains crucial for initial triage, its limitations in detecting subtle cognitive deficits underscore the need for supplementary tools like the SCAT or MACE, which provide broader insight into the clinical picture.
Early recognition and prompt assessment are critical. Healthcare professionals working in environments where mTBI is prevalent—such as sports fields, emergency departments, and military units—should receive appropriate training to identify early symptoms and administer validated tools effectively. Integrating symptom-specific questionnaires, such as the Post-Concussion Symptom Scale, during both acute and follow-up visits allows for monitoring symptom persistence or resolution, thus guiding decisions about return to normal activities.
Given the growing body of evidence supporting their utility, clinicians should consider incorporating emerging technologies, such as portable EEG devices and blood-based biomarkers, into diagnostic pathways when available and practical. However, any such integration must be accompanied by standardised protocols to ensure consistency and interpretative accuracy. Further, clinicians should maintain a high index of suspicion for atypical presentations in populations such as children, older patients, and individuals with comorbid conditions, where mTBI symptoms may diverge from conventional profiles or be under-reported.
A key recommendation is to establish and utilise baseline assessments, particularly in settings with recurrent mTBI risk, such as athletics and military operations. Baseline data allow post-injury comparison and enhance the reliability of tools like SCAT or neurocognitive testing. When baseline data are unavailable, clinicians should interpret assessment results cautiously and consider a more conservative management strategy to ensure patient safety.
Communication plays a central role in effective mTBI management. Clinicians should ensure patients and their families understand the nature of the injury, expected recovery timelines, and the importance of follow-up care. Standardising discharge instructions and educational materials can help reinforce early symptom monitoring at home and encourage timely re-presentation if new or worsening symptoms emerge.
Finally, it is recommended that clinical practice incorporate a structured follow-up plan for patients diagnosed with mTBI. While many individuals experience symptom resolution within two weeks, others may develop persistent symptoms requiring multidisciplinary intervention, including neuropsychology, physiotherapy, or occupational therapy. Regular reassessment using consistent assessment tools permits more precise tracking of recovery and helps identify cases requiring specialised referral.
Incorporating these recommendations can improve diagnostic accuracy, streamline management, and support better short- and long-term outcomes for individuals affected by mTBI. Consistency in applying assessment tools such as the SCAT and Glasgow Coma Scale, alongside technological advances and patient education, forms the foundation of enhanced clinical practice in this challenging and evolving area of care.
